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(SOADAS). Eleven papers were included in a critical review of the
instruments. Development histories and psychometric properties
were largely adequate though each instrument was lacking in
some aspect. Each instrument has its individual merits; the 8-item
DTSQ, 7-itemDTTQ and 6-item SOADAS offer brevity, while the
21-item Diab-MedSat offers a more detailed approach. The
DTTQ and SOADAS focus speciﬁcally on tablet treatment, while
the DTSQ and Diab-MedSat enable within-groups comparisons
when changing treatment from tablets to insulin. CONCLU-
SIONS: The DTSQ, the Diab-MedSat, the DTTQ and the
SOADAS have acceptable development histories and psychomet-
ric properties, though evidence for both could be strengthened in
certain areas to fulﬁl the FDA’s requirements. Given the differing
focus/length of each instrument, selection will also depend on
study objectives.
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BACKGROUND: Diabetes is a common chronic condition
affecting several millions of people in the United States. Insulin
supplementation is essential for controlling diabetes. However,
not all patients are receptive to taking injectable insulin and are
therefore more likely to be noncompliant with therapy. Inhaled
insulin is as efﬁcacious as subcutaneous insulin, but patients’
willingness to pay for inhaled insulin and the factors that affect
their willingness to pay (WTP) are unknown. OBJECTIVES: To
determine (1) the relationship of patient satisfaction with current
insulin therapy and demographic factors on WTP for inhaled
insulin, and (2) predictors of patients’ WTP for inhaled insulin.
METHODS: Exploratory cross-sectional study design using a
random sample of diabetic patients from a national database.
Data were collected using a mailed survey that focused on a
patient satisfaction, willingness to pay, and general patient infor-
mation. Patient satisfaction was measured the Patient Satisfac-
tion with Insulin Therapy (PSIT) scale. Data were analyzed using
SPSS v.15.0 with an a priori alpha of 0.05. Descriptive statistics,
Point-biserial and Pearson correlations, Chi-Square analyses,
and Linear and Logistic regression modeling were conducted.
RESULTS: One hundred twenty-eight patients responded.
Annual household income, type of diabetes, patient satisfaction
with current insulin therapy, gender, number of insulin injections
per day, and current cost of insulin therapy were found to have
a signiﬁcant relationship with WTP. Annual household income
and patient satisfaction predict patients’ WTP, X2 (9,
N = 114) = 27.45, p = 0.001.While, current cost of insulin
therapy and annual income were found to be signiﬁcant predic-
tors of how much patients were willing to pay for inhaled insulin,
R2 = 0.242, p < 0.05. CONCLUSIONS: Patients with higher
annual incomes and those who are dissatisﬁed with their current
insulin therapy are willing to pay for inhaled insulin. Also,
patients with higher annual income and higher current cost of
insulin therapy are willing to pay more for inhaled insulin.
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OBJECTIVES: To compare treatment satisfaction (TS) associ-
ated with insulin administration in type 2 diabetes subjects
treated with either insulin glargine based regimens or Neutral
Protamine Hagedorn (NPH) insulin based regimens for at
least 6 months. METHODS: As part of a comparative, non-
interventional, multi-centre, cross-sectional study in a primary
care setting in Germany, patients with insulin-dependent type 2
diabetes completed the Insulin Treatment Experience Question-
naire (ITEQ), a new condition-speciﬁc instrument assessing TS,
and the Diabetes Treatment Satisfaction Questionnaire (DTSQs).
The ITEQ contained 28 items among seven subscales (leisure
activities, psychological barriers, handling, diabetes control,
dependence, weight control, sleep); forming an ITEQ total score
transformed as 0 to 100, with 100 indicates high treatment
satisfaction. To examine differences between the two treatment
groups Mann-Whitney U tests were used. Multivariate linear
regression models were performed to determine differences
between treatment groups, controlling for sociodemographic and
diabetes-related characteristics, respectively. RESULTS: Overall,
1858 individuals were enrolled in the study, and TS analyses were
conducted with data from the 1,602 per protocol patients (982
insulin glargine and 620 NPH insulin). Demographic data of
patients receiving either insulin glargine or NPH insulin were
similar. DTSQs satisfaction score, ITEQ subscales and ITEQ
total score differed between therapy regimens and were signiﬁ-
cantly higher in the insulin glargine group (DTSQs: 29.9  5.5
vs. 29.2  5.7, p = 0.01; ITEQ total score: 71.5  13.1 vs.
67.6  13.9, p < 0.001). Results of the regression models indi-
cate that differences between the groups were stable after adjust-
ment. CONCLUSIONS: Our results indicate that insulin glargine
was associated with signiﬁcant higher treatment satisfaction
compared to NPH insulin among patients with type 2 diabetes.
The results suggest that the use of insulin glargine provide an
additional treatment beneﬁt for type 2 patients with insulin
dependent diabetes mellitus.
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OBJECTIVES: 1) To compare means of calories burnt by exer-
cise, compliance, eating behavior score, diabetes knowledge,
BMI and Fasting Blood Glucose (FBG) between gender control-
ling for age; 2) To ﬁnd correlations between calories burnt by
exercise, compliance, eating behavior score, diabetes knowledge,
age, BMI and FBG; 3) To estimate Hierarchical Stepwise
Multiple Regression Analysis (MRA) model to predict FBG.
METHODS: A cross-sectional deductive survey by telephone
interviewing and accessing clinical data were employed to inves-
tigate relationship between health behavior factors namely—
calories burnt by exercise, compliance, eating behavior score,
demographic data and FBG of 200 type 2 diabetes patients at
Saraburi Hospital 2008, randomly generated by computer.
RESULTS: Total sample size of 200 (100%) diabetes patients,
mostly 138 (69.00%) were female, 62 (31.00%) were male with
average age 59.34  11.99 years, average BMI 26.79  2.50,
average calories burnt per week 2777.24  2420.89, average
compliance score 12.37  7.13, and average FBG 161.25 
54.10. Cronbach’s Alpha coefﬁcient of Sorofman’s Compliance
scale for constructs “right time” and “right amount” were
0.8157, and 0.8526 respectively and Auamnoy Eating Behavior
Scale was 0.7915. ANCOVA conﬁrmed that FBG, compliance,
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diabetes knowledge, eating behavior score and BMI between
male and female were not signiﬁcantly different when controlling
for age (p > 0.05) however, calories burnt by exercise between
male and female patients were signiﬁcantly different (p < 0.05).
Partial correlation conﬁrmed that diabetes knowledge, calories
burnt by exercise and age were inversely signiﬁcantly correlated
to FBG (r = -0.51**, -0.36**, -0.28* with p < 0.01, p < 0.01,
p < 0.05 respectively). MRA model proved that ﬁve factors; dia-
betes knowledge, calories burnt by exercise, gender, age, and
BMI were the signiﬁcantly predictors of FBG (Beta= -0.40,
-0.25, -0.11, and -0.10 with p < 0.01, 0.01, 0.01, 0.05, 0.05,
R2 = 0.26). CONCLUSIONS: Diabetes knowledge, calories
burnt by exercise and gender were three signiﬁcantly most inﬂu-
ence factors for predicting Fasting Blood Glucose. The diabetes
patients should be educated on how to cope with diabetes and to
do the more exercise.
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OBJECTIVES: The goals of treatment for type 2 diabetes are to
prevent diabetic complications through intervention for hyperg-
lycaemia, hypertension and hyperlipidaemia. The aim of this
study was to describe the type of treatment patients receive and
their attainment of treatment goals in an unselected population
of patients with type 2 diabetes. METHODS: In 2007, 35 GP
centres in all areas of Norway (response rate 25%) had eight
types of data (including laboratory tests, drug prescriptions)
extracted from their electronic record systems for all patients
who had consulted for type 2 diabetes in 2000 or later. Data were
analysed with descriptive measures and regression techniques.
RESULTS: There has been a trend towards lower HbA1c values
since 2000, and 53% of the last recorded value was below 7%.
The proportion of patients with HbA1c value below 7% was
57% for patients on one oral antidiabetic drug, but 30% for
those on ﬁve drugs. At the last visit, 39% of the patients had
blood pressure below 135/85, and 36% of all patients were on
antihypertensive treatment. While 50% of patients without anti-
hypertensive drug had a blood pressure below 135/85, the pro-
portions were 36% for those on one drug and 35% fore those on
two drug. While the mean total cholesterol was 5.6 mmol/l in
2000, the value was 4.9 in 2007. At the last consultation, 51% of
the patients had a total cholesterol value below 5.0 mmoml/l.
CONCLUSIONS: In a general diabetes two population,
glyceamic control and lipid levels have improved over the last-
seven years. Use of multiple oral antidiabetics is an indicator of
poor glycaemic control.
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OBJECTIVES: To assess the management of severe hypoglycae-
mic events (SHEs) in Germany, Spain and the UK. METHODS:
A total of 639 adults with Type 1 (n = 319) or insulin-treated
Type 2 diabetes (n = 320), of median age 38 [range, 16–84] and
62 years [19–94], respectively, and with median diabetes dura-
tion of 16 [1–58] and 13 years [1–49], respectively, who had
experienced 1 SHEs (requiring external help for recovery) in
the preceding 12 months provided information on diabetes
history and SHE management by questionnaire. Patients were
grouped by where the SHE was treated: Group 1, community
(lay person); Group 2, community (health care professional);
Group 3, inside hospital. RESULTS: A total of 69% of patients
had >1 SHE/year (median, 2–3). Most events (69%) occurred
at home, mainly (74%) during the day (6 a.m.–10 p.m.), most
commonly because of insufﬁcient or irregular meals (45% of
patients). Most patients (168; 68%) had normal hypoglycaemia
awareness (Likert scale scores; not assessed in UK); impaired
hypoglycaemia awareness was commonest in Group 3 (17;
11.3%) and least common in Group 1 (11; 3.3%) (p = 0.003,
chi-square test). Hypoglycaemic coma was commonest in
Group 3 (58.7%) and least common in Group 1 (13.6%).
Coma prevalence was associated with impaired awareness
(p < 0.0001). More patients in Germany (58%) stayed in the
hospital for >24h than in Spain (16%) or the UK (28%)
(p < 0.0001). Following a SHE, more patients in Groups 2 and
3 than in Group 1 consulted their physician, tested blood
glucose more frequently, adjusted insulin dose and/or received
further education. Blood glucose tests increased by 2/day
(median) in the 4 weeks post-SHE and 293 (46%) patients
changed insulin dose. CONCLUSIONS: Other than duration of
in-patient stay, the frequency, cause and management of SHEs
were similar across countries despite cultural and health care
system differences. SHEs represent a substantial resource
burden on health care systems.
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OBJECTIVES: Both insulin detemir and insulin glargine have
been approved for reimbursement on the Australian Pharmaceu-
tical Beneﬁts Scheme (PBS). Prior to their listing, intermediate
acting insulin isophane (NPH) was the only PBS listed basal
insulin. Determination of the dose relativity from the randomised
clinical trials was confounded due to strict titration algorithms
and protocol requirements. Therefore to ascertain the dose rela-
tivity in clinical practice, a chart audit was conducted.
METHODS: The audit was carried out in six practices; ﬁve
specialist and one primary care. The inclusion criteria were:
diagnosis of type 1 diabetes, switched to detemir or glargine
between 01 October 2006 and 31 May 2007 and at least 6
months of follow-up. To ensure that there was no systematic
bias, the investigator was instructed to select every nth ﬁle with n
being a function of the number of patients who were eligible for
participation. RESULTS: Records were obtained on 87 patients
who switched to detemir and 77 patients who switched to
glargine. The baseline characteristics of patients were similar for
both groups with the exception that 30% (26/87) of patients
switched to detemir and 48% (37/77) of patients switched to
glargine were having once daily injections of NPH. Despite a
regulatory label for only once daily dosing for glargine, the audit
established that 25% of glargine use was twice daily. There was
no statistically signiﬁcant difference in baseline pre-switch NPH
doses to either detemir (0.44 to 0.45 U/kg/day) or glargine (0.45
to 0.43 U/kg/day). The dose relativity between detemir and
glargine ﬁnal doses was one to one. The audit also demonstrated
no statistically signiﬁcant difference in HbA1c between detemir
and glargine (8.0% & 7.8%, respectively). CONCLUSIONS:
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